TP53 and cancer: Therapy induced defects in G1 checkpoint, e.g., due to faulty p53, a critical gatekeeper of the G1 phase, can drive cancer cells towards increased dependency on the G2 checkpoint to repair DNA damage (22), and thus, targeting G2 checkpoint has been proposed as an anti-cancer strategy in these cancer models (23).